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Rene H. Wijffels, and Dirk E. Martens*In a Chinese Hamster Ovary (CHO) cell fed-batch process, arrest of cell
proliferation and an almost threefold increase in cell size occurred, which is
associated with an increase in cell-specific productivity. In this study,
transcriptome analysis is performed to identify the molecular mechanisms
associated with this. Cell cycle analysis reveals that the cells are arrested
mainly in the G0/G1 phase. The cell cycle arrest is associated with significant
up-regulation of cyclin-dependent kinases inhibitors (CDKNs) and down-
regulation of cyclin-dependent kinases (CDKs) and cyclins. During the cell
size increase phase, the gene expression of the upstream pathways of
mechanistic target of rapamycin (mTOR), which is related to the extracellular
growth factor, cytokine, and amino acid conditions, shows a strongly
synchronized pattern to promote the mTOR activity. The downstream genes
of mTOR also show a synchronized pattern to stimulate protein translation
and lipid synthesis. The results demonstrate that cell cycle inhibition and
stimulated mTOR activity at the transcriptome level are related to CHO cell
size increase. The cell size increase is related to the extracellular nutrient
conditions through a number of cascade pathways, indicating that by rational
design of media and feeds, CHO cell size can be manipulated during culture
processes, which may further improve cell growth and specific productivity.Dr. X. Pan, A. A. Alsayyari, Prof. R. H. Wijffels, Dr. D. E. Martens
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Chinese hamster ovary (CHO) cells are
currently the predominant expression sys-
tem for the production of biopharmaceut-
icals. In order to increase the volumetric
productivity of CHO cell cultures, advances
have been made with respect to media
development, process optimization, and
cell line engineering. To obtain an in-
creased volumetric productivity without
increasing cell density, an increase in
specific productivity (qp) is needed. For
this, several strategies have been described,
including hyperosmotic pressure,[1] cell
cycle arrest,[2] and mild hypothermia.[3]
In these studies, the increase in qp was
found to be correlated with an increase in
cell size. Furthermore, Kim et al.[4] showed
that the enhancement of the qp was linearly
correlated with an increase in cell size for
nine CHO cell clones generated using the
same transfection process. Edros et al.[5]
and Khoo and Al-Rubeai[6] showed that
the increase in qp was directly related to
the increase in cell volume due to enhance-ment of the transcription, translation, and secretion machinery.
The regulation of mammalian cell size is controlled by cell
growth and cell division through multiple complex mechanisms
and pathways.[7,8] Proliferating cells are maintained at a more or
less constant cell size by doubling their cell mass before each cell
division. Themechanistic target of rapamycin (mTOR) signaling
pathway has shown to be a central controller of cell size by
controlling biomass synthesis.[9–11] Dreesen and Fussenegger[12]
showed that an increase in the mTOR activity led to an increase
in CHO cell size together with an up to fourfold higher protein
content per cell, and a fourfold higher specific productivity of
recombinant IgG. Furthermore, manipulation of the positive or
negative upstream pathways of mTOR has been shown to
influence mammalian cell size. Backman et al.[13] showed that
deletion of a mTOR inhibitor, phosphatase, and tensin homolog
(PTEN), resulted in mammalian cell size increase. McVey
et al.[14] showed that the knock-out of another mTOR inhibitor,
tuberous sclerosis complex 2 (TSC2), also resulted in larger
CHO cells with higher protein synthesis and an over twofold
increased qp. In addition, an increase in the PI3K/Akt pathway
activity which positively regulates mTOR resulted in cell size
increase in both mammals and Drosophila.[8]nal Published by Wiley-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comAsmentioned before, cell size is also altered during the cycle of
each cell division. Cell size and biomass content per cell increase
during the interphase (G1, S, and G2 phase) of the cell cycle. A cell
reaches the largest cell size at the endof theG2 phase,which is two
times the size as the cell in the G1 phase, before the mitosis
(M phase) takes place.[15] Hence, cell cycle control is also a way to
increase cell size. In the study of Bi et al.,[16] overexpression of the
p21CIP1 induced G1-phase cell cycle arrest in a CHO cell culture,
which resulted in nearly fourfold increase in cell volume aswell as
in qp. In the study of Fomina-Yadlin et al.,
[17] the addition of small
molecule inhibitors that arrest mammalian cells in the G1 phase
orG1/S transition resulted in a 1.5-fold increase in cell volumeand
qp. The regulation of cell size is a complex process that involves a
large network including both cell growth and division. Until now,
the molecular mechanism of cell size regulation is not fully
understood.
In our recent study,[18] a cell number increase phase followed by
a cell size increase phase was observed in a CHO cell fed-batch
cultureprocessusingActiCHO-PasbasalmediumandActifeedA/
B as feeds (from now on called the ActiCHO process). In the cell
size increase phase, cell division comes to a halt but cell growth
continues in the form of an increase in cell size. In this process, a
standard feeding approachwasused.No special strategies, such as
lowering of the temperature, were used to arrest the cell cycle. The
increase incell volumewasdue toan increase incell dryweight asa
result of increases in protein, lipid, and carbohydrate content per
cell. Furthermore, an increase in qp was observed, which linearly
correlatedwith the increase in cell volume. Themetabolic changes
associated with the cell size increase were studied in detail using
flux balance analysis; however, the cause and molecular mecha-
nisms for the cell size increase remained unclear. Transcriptome
analysis has been used as a powerful tool to better understand
thephysiologyofCHOcell lines.[19–23] Theaimof thepresentstudy
is to obtain more insights into the cause and the molecular
mechanisms underlying the CHO cell size increase using
transcriptome analysis.
Due to the dynamic nature of the fed-batch culture (e.g.,
continuously changing cell density and nutrient and waste
metabolite concentrations), many genes will be regulated over
time of which only a part is related to the cell size increase. In
order to enrich the genes that are related to cell size regulation,
we used a FortiCHO process (FortiCHO basal medium fed with
Efficient feed A/B) which did not result in cell size increase as a
“filter.” The FortiCHO process is different in more aspects than
only the cell size increase and consequently, not all genes that
have a different expression profile between both processes will
be related to the cell size increase. Nevertheless, many genes
show an identical expression profile and are thus not uniquely
related to the cell size increase.2. Experimental Section
2.1. Cell Line and Fed-Batch Process Set-Up
A suspension CHOBC cell clone (BC-P, provided by Bioceros
Holding BV) producing a recombinant immunoglobulin G1
(IgG1) as previously described[24] was used in this study. Two
fed-batch processes using the same cell line but differentBiotechnol. J. 2019, 14, 1800156 1800156 (2 of 12) © 2018 Themedium-feed systems are studied. One process resulted in cell
size increase whereas for the other this was not the case.1)AuthThe ActiCHO culture process. Triplicate fed-batch cultures
were conducted in 10 L Sartorius bioreactors (sartorius
stedim) controlled by BIOSTAT B-DCU II. Each bioreactor
was inoculated with a starting density of 3 105 viable cells/
mL at a starting volume of 5 L. Culture temperature was
controlled at 37 C, dissolved oxygen (DO) was controlled at
40% by pure O2 flow enrichment, pH was controlled at 7.2 by
CO2 flow enrichment and 0.5M NaOH. The feeding strategy
was the same as described in Pan et al.[18] Briefly, from day 3
on, 4.5% ActiCHO feed A and 0.45% ActiCHO feed B (both
from GE Healthcare) per culture volume per day were fed to
each reactor daily. 45% (w/w) glucose solution was added to
each bioreactor, to ensure that the glucose concentration
stayed above 5mM at the next feeding point.2) The FortiCHO culture process. Triplicate fed-batch cultures
were conducted in 1 L DASGIP bioreactors (Eppendorf).
Each bioreactor was inoculated with a starting density of
3 105 viable cells/mL at a starting volume of 500mL.
Culture temperature, DO, and pH are controlled at the same
set-point as the ActiCHO process with similar approaches.
From day 3 on, Efficient Feed A/B (with a 1:1 combination)
was added to each bioreactor as one bolus. The feeding
strategy was similar as described in Pan et al.[24] Briefly, the
daily volume added was calculated based on the specific
glucose consumption rate, to ensure that the glucose
concentration stayed above 5mM at the next feeding point.2.2. Daily Sampling and Analysis
A sample was taken from each bioreactor every day before the
feed addition. Viable cell density (VCD), viability, and cell
diameter were measured using a CedexHiRes analyzer (Inno-
vatis; Roche) for the ActiCHO process, and a TC20 cell counter
(Bio–Rad) for the FortiCHO process. Three milliliter of the
sample was spun down at 300 g for 5min (Heraeus Multifuge
X3R, Thermo Scientific). The cell pellet was collected and the
total RNA was extracted using 3mL TRIzol reagent (Invitrogen)
and stored at 80 C for later transcriptome analysis. For cell
cycle analysis, 2mL cell culture sample was spun down at 300 g
for 5min. The cell pellet was fixated in 2mL ice-cold 70% ethanol
overnight at 20 C. Next, the cells were prepared and stained
using Cycletest Plus DNA Reagent Kit (BD Biosciences) and the
cell cycle was analyzed on the BD Accuri C6 Flow Cytometer (BD
Biosciences).2.3. Transcriptome Analysis
For each bioreactor of the ActiCHO and FortiCHO process,
transcriptome analysis was done for the samples taken on
culture days 3, 5, and 7. Total RNAwas purified using the RNeasy
Mini kit (Qiagen, Valencia, CA). Affymetrix GeneChip CHO
Gene 2.1 STArrays (Affymetrix, Santa Clara, USA) were used for
transcriptome expression profiling. The detailed method wasors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
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amount of RNA was labeled by the Whole-transcript
Sense Target Assay (Affymetrix) and hybridized according to
the manufacturer’s instructions. Quality control and data
analysis were done as described in ref. [25]. Normalized
expression estimates of probe sets were computed by the robust
multi-array analysis (RMA),[26] using R/Bioconductor package
AffyPLM.[27] The well-annotated reference sequences are based
on the CriGri_1.0 genome assembly NCBI reference sequence
project (RefSeq) Release 72, which resulted in 60626 annotated
sequences (transcripts profiles) (custom CDF v20). After
averaging the expression levels of probe sets targeting the same
gene, expression data for 20858 unique genes were obtained,
which was used for all subsequent analysis. Linear models
(Limma package) were used to identify the differential expressed
genes taking into account correlation due to the repeated
sampling from the same bioreactors followed by an intensity-
based moderated t-statistic.[28,29] Gene regulations that satisfied
the criterion of Benjamin and Hochberg false discovery
rate (FDR.BH) <5% and absolute fold-change (FC) >1.4 were
defined to be significant and were subjected to KEGG pathways
over-representation analysis using Fisher’s exact test. These
cut-off values are applied to reduce the number of false-positive
genes and the background noises that are picked up by
the differential gene analysis.[23,30–33]3. Results and Discussion
3.1. Cell Growth, Cell Size, and Cell Cycle Dynamics
The cell growth characteristics including VCD, viability, and
average cell diameter are shown in Figure 1. The VCD profile is
similar for both processes (Figure 1A). The cell viability in the
ActiCHO process (black-dashed line) started to decrease on day
10, while in the FortiCHO process (red dashed line) the decrease
started on day 7. Figure 1B shows that for the ActiCHO process,
upon the stop of cell division on day 5, the cells continued to
grow in size, from an average cell diameter of 17 μm on day 4, to
24 μm on day 10. Our previous study on the ActiCHO process[18]
showed that the size increase was proportional to the increase in
biomass content. In contrast, the average cell diameter in the
FortiCHO process went down gradually from 17 μm on day 1, to
15 μm on day 7. The sharp decrease in cell diameter after day 7
was caused by cell death resulting in the formation of small
particles which were probably apoptotic bodies. In addition, the
monoclonal antibody product titre profiles of both processes are
presented in Figure S3, Supporting Information.
To study the cell cycle status during the cell size increase of the
ActiCHO process, the cell cycle distribution was measured. In
Figure 1C, the propidium iodide (PI) DNA stain intensity area
(FL2-A) which is a measure of the DNA content, is plotted
against the forward scatter area (FSC-A) which is a measure of
cell size for days 3, 5, 7, and 9. A clear cell cycle distribution can
be seen at FL2-A intensities between 10 and 2 000 000. The
populations observed above a FL2-A of 2 000 000 are probably
due to aggregates. On day 3, they represent about 3% of the total
events and they gradually disappear with the progression of
culture time to about 1.5% on day 9. With culture time aBiotechnol. J. 2019, 14, 1800156 1800156 (3 of 12) © 2018 Thepopulation develops at very low FL2-A intensities which probably
represents cell debris and apoptotic bodies and agrees with
the slight decrease in viability observed. It can be seen from
Figure 1C that:1)AuthThe cells in the G2/M phase are larger (higher FSC-A) than
the cells in the G0/G1 phase for all the analyzed culture days.
This agrees with the fact that the volume and biomass per cell
increase from the G1 phase until the G2/M phase.
[8]2) Going from days 3 to 9, it can be seen that the S-phase
population disappears and cells are arrested in both the
G0/G1 and the G2/M phase. When the cell debris population
is gated out from the total population, the G0/G1 population
presents 58% of the total population on day 3 and increases to
85% on day 9, whereas for the G2/M population the number
decreases from 31% on day 3 to 11% on day 9 (data not
shown). The result agrees with the fact that after day 5 cell
proliferation has stopped in the ActiCHO process
(Figure 1A). In several CHO cell culture processes,
hypothermia,[34–36] hyperosmotic stress,[1,37] and cell cycle
inhibitors[2,38,39] were applied that mediated a G0/G1 arrest
without influencing G2/M phase. This was, however, not the
case in the present study where cell cycle arrest occurred in
both G0/G1 and the G2/M phase. In theory, cells at twice the
FL2-A intensity could be aggregates of two cells arrested in
the G1 phase.3) Cell size starts to increase after day 5 in both the G0/G1 and
G2/M phase, as shown by the increase in FSC-A values. The
extent of the size increase in both phases is comparable. This
indicates that the cell size increase is not influenced by the
cell cycle phase the cell is arrested in. Rather, the cell biomass
growth and cell cycle arrest seem to be two independent
processes.
In summary, the cell cycle analysis confirms that the cell cycle
arrest occurs in both the G0/G1 and the G2/M phase of the
ActiCHO process. Moreover, the cells arrested in both phases are
able to grow in cell size.3.2. Transcriptome Analysis
Transcriptome analysis using Affymetrix CHO Gene micro-
arrays was performed to gain insights into the molecular
mechanism underlying the cell cycle arrest and the cell size
increase. The same amount of mRNA was brought on CHO
Gene microarrays for each sample during the transcriptome
analysis. Therefore, a change in gene expression is relative
against the total transcripts and is not influenced by the possible
fact that larger cells have a higher overall transcriptome activity.
The sample points on culture days 3, 5, and 7 of the two
processes are selected for transcriptome analysis. Day 3
represents the middle of the cell proliferation phase where
the cell size is still similar in both processes (Figure 1A). For the
ActiCHO process, day 5 represents the start of the cell size
increase phase whereas day 7 represents the middle of the cell
size increase phase. For the FortiCHO process, day 5 represents
the stop of exponential growth phase whereas day 7 represents
the end of the stationary phase and the start of the death phase.ors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Figure 1. Cellgrowth,cell cycle,andtranscriptomeprofilesof the fed-batchcultureprocesses.A)VCD(106 cells/mL,solid lines)andviability (%,dashed lines),and
B)averagecelldiameter (μm)of theActiCHOprocesspublished inPanetal.[18] (roundmark,black lines)andtheFortiCHOprocess(squaremark, red lines).Theerror
barsshowthestandarddeviationforthreebioreactorsofeachprocess.InA),onlythepositiveerrorbarsareshowninordertoavoidoverlap.C)Thecellcycleanalysisfor
theActiCHOprocessondays3, 5, 7, and9. Thepropidium iodide (PI)DNAstain intensity (FL2-A) is plottedagainst the forwardscatter area (FSC-A). FL2-A indicates
theamountofDNAinacellwhileFSC-Aindicatesthesizeofacell.ThesampleeventsathighFL2-Aintensity(>2000000)are likelycausedbycellaggregates.D)Score
plot generated from the transcriptome results of the ActiCHO (filled blue markers) and the FortiCHO (open red markers) processes. The same sample marker
represents the sample taken from the same bioreactor. Samples taken from the same day and the same process is marked in a circle. Three biological replicates
are included.E)Venndiagramof thenumberofgenes that aredifferentially regulated fromdays3 to7comparedbetween the twoprocesses.Uppernumbers indicate
up-regulation as shown by the green arrow, lower numbers indicate down-regulation as shown by the red arrow.
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Table 1. Top 10 fold-changes of up- and down-regulated genes in the
ActiCHO process from days 3 to 7.
Gene symbol Fold-change Gene function in biological process
Top 10 up-regulation
Fam213a 188.20 Redox regulation
Ranbp3l 145.63 Protein transport
Sema4d 24.12 Differentiation
Spp1 20.56 Cytokine activity, extracellular matrix binding
Slc6a12 19.64 Osmotic regulation/transport
Myl9 14.68 Myosin regulation
Pcp4l1 14.02 Protein coding
Scn7a 13.78 Sodium channeling
S100a4 11.42 Protein binding
LOC100768899 11.40 Protein coding
Top 10 down-regulation
Kif15 17.19 Mitosis, spindle assembly
Ect2 16.84 DNA synthesis, cell cycle
Nuf2 16.73 Mitosis, chromosome segregation
Rrm2 16.55 DNA synthesis, cell cycle
LOC100752904 15.90 nucleosome assembly
Ccna2 14.97 Cell cycle
Bub1b 14.87 Mitosis, chromosome segregation
Cenpw 14.77 Mitosis, chromosome segregation
Ccnb2 14.63 Cell cycle
Aurkb 14.08 Mitosis, chromosome segregation
The gene functions are searched against the Gene Ontology (GO) and UniProt
database. The results generated are based on three bioreactor cultures.
www.advancedsciencenews.com www.biotechnology-journal.com3.2.1. Transcriptome Profiles for Culture Processes With and
Without a Cell Size Increase
The principal component analysis (PCA) (Figure 1D) shows the
overall variation in gene expression for all analyzed samples.
PC1 and PC2 contribute 26 and 18% to the total variation,
respectively. The contribution for the rest of the PCs are minor
(e.g., 7% of the PC3) and are not considered. PC1 and PC2 both
capture a change in gene expression in time as well as a
difference in gene expression between both systems (ActiCHO
and FortiCHO). The Venn diagram (Figure 1E) shows the
differential gene expression between days 3 and 7 which is
unique to the ActiCHO and FortiCHO process, andwhich occurs
in both processes. Genes are considered differentially expressed
between the 2 days if the FDR.BH value is smaller than 5% and
the absolute fold change is larger than 1.4 (see section 2.3). For
the total 20 858 probed genes on the CHO gene array, 5684 genes
(25%) are regulated in either the ActiCHO or FortiCHO process.
In the ActiCHO process, 4824 genes (total number of genes in
the blue circle) are differentially expressed, of which 3037 (total
number of genes in the blue circle excluding the number of
genes that overlap with the red circle) are unique to the ActiCHO
process, and of which 1787 (overlap between the two circles) are
also differentially expressed in the FortiCHO process in the same
direction.
From the significantly regulated genes in the ActiCHO
process from days 3 to 7, we first selected the top 10-fold-changes
of the up- and down-regulated individuals (Table 1). Compared to
the top 10-up- and down-regulated genes in the ActiCHO
process, many of these genes also showed significant (fold-
change >1.4, FDR.BH <5%) regulations in the FortiCHO
process, however, the fold-changes are much smaller (see
Supporting Information 1). In the top 10 up-regulated genes in
the ActiCHO process, the Fam213a and Ranbp3l genes have
extremely high fold-changes (188 and 145, respectively)
compared to the others. The expression of Fam213a was shown
to protect cells from oxidative stress.[40] Oxidative stress in cells
can be caused by increased reactive oxygen species (ROS) which
are reduced forms of oxygen, such as superoxide radical (O2
),
hydrogen peroxide (H2O2), and hydroxyl radical (HO
). The DO
tension during all the cultures in this study was maintained at
40%. It is unlikely that a high extracellular DO was the cause of
the ROS formation. However, increased oxidative metabolism
was reported in CHO cells with increased mAb production as
well as with increased cell size.[16,41] In our previous study,[18] a
1.5-fold increase in cellular oxygen consumption flux was
observed during the size increase phase of the ActiCHO process.
This might be related to the formation of ROS in cells and
subsequently the overexpression of Fam213a. If this was the
case, the extreme overexpression of Fam213a would likely be a
response of the cell size increase, rather than the cause of it.
Another extremely up-regulated gene, Ranbp3l, was reported to
be involved in bone morphogenetic protein (BMP) signaling and
regulating mesenchymal stem cell differentiation.[42] The exact
function of this gene in the context of cell size increase in CHO
cells is however unknown. In addition, two genes involved in
osmotic regulation (Slc6a12 and Scn7a) are significantly up-
regulated. This could be related to the increase in culture
osmolality due to the feed addition which was described in ourBiotechnol. J. 2019, 14, 1800156 1800156 (5 of 12) © 2018 Theprevious study for the ActiCHO process.[18] Next to the top 10
up-regulated genes, also the top 10 down-regulated genes are
listed in Table 1, together with the functions of these genes in
biological processes. As can be seen, all the top 10 down-
regulated genes are involved in cell cycle regulation and mitosis.
This agrees with the inhibition of cell cycle progression as
described in the previous section. Some of these genes are
further discussed in the next section.
In order to get a better understanding of the relationship
between gene regulation and the cell size increase, a targeted
approach is used in the next sections. From the genes that are
differentially expressed in the ActiCHO process (the blue circle
in Figure 1E), a subset of genes (500 genes in total) are
examined in more detail. This subset of genes are selected based
on the fact that they are known to play critical roles in cell cycle
progression and biomass growth as well as in the signaling
pathways involved in these processes. The regulation of these
genes is compared to that in the FortiCHO process, to enrich
genes that are uniquely related to the cell size increase. An
overview of the selected pathways is shown in Figure 2. Note that
some pathways in Figure 2 are known to be post-transcriptional
regulated (e.g., by phosphorylation), and it is not completely
clear whether they are regulated transcriptionally as well.
Thus, genes that are not differentially expressed could still beAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Figure 2. Overview of the signaling pathways regulating cell cycle arrest and the cell size increase. CDK, cyclin dependent kinases; Cycs, cyclins; TGFβ,
transforming growth factor beta; CHK, checkpoint kinases; p53, tumor protein p53; p16, p21, and p27, cyclin-dependent kinase inhibitors, p16INK4a,
p21CIP1, and p27KIP1, respectively; TNFα-IKKα/β, tumor necrosis factor-α (TNFα)—inhibitor of nuclear factor-κB kinase-β (IKKβ); AKT, Protein Kinase B;
TSC1/2, tuberous sclerosis complex 1/2; PTEN, phosphatase and tensin homolog; PI3K, phosphatidylinositol 3’-kinase; Rheb, Ras homolog enriched in
brain; mTOR, mechanistic target of rapamycin; V-ATPase, vacuolar Hþ-ATPase; AMPK, AMP-activated protein kinase; GAS, growth arrest specific;
SREBP, sterol responsive element binding; 4EBP, eukaryotic translation initiation factor 4E binding protein; Lamtor, late endosomal/lysosomal adaptor;
S6K, P70-S6 Kinase 1; RagA/B and RagC/D, Rag heterodimers A/B and C/D.
www.advancedsciencenews.com www.biotechnology-journal.comimportant due to post-transcriptional regulation. However, if
the transcription of these pathways shows a synchronized
regulation, it may still mean that at least part of the regulation is
done transcriptionally, and it may still give an indication of these
gene functions in cell size increase.3.2.2. Gene Regulation Related to Cell Cycle Arrest
Figure 2A,B shows the pathways related to the cell cycle
regulation. The genes of these pathways that are significantly
regulated from culture days 3 to 7 in the ActiCHO process are
presented and their changes in expression are compared to
those in the FortiCHO process (Table 2). Mammalian cell
cycle regulation involves the participation of two classes of
proteins: the cyclin-dependent kinases (Cdks), and their
binding partners, cyclins (Cycs).[43] Binding of a Cdk to a
Cyc forms an active complex that enables the cell cycle to
progress through a specific phase. For both processes inBiotechnol. J. 2019, 14, 1800156 1800156 (6 of 12) © 2018 TheTable 2, down-regulations of various cdks genes and their
binding partner cyclin genes (Cycs) are observed, which agrees
with the stop of cell division in both processes. However, the
extent of down-regulation (fold change) and significance (FDR.
BH) for these genes are much higher in the ActiCHO process
than in the FortiCHO process, indicating that the cell cycle
arrest is stronger in the ActiCHO process.
For the ActiCHO process, especially one CycA gene (Ccna2,
FC¼14.97, FDR.BH< 0.5%), two CycB genes (Ccnb1, FC¼
11.20, FDR.BH< 0.5%, and Ccnb2, FC¼14.63, FDR.BH
< 0.5%), and to a lesser extent a Cdk gene (Cdk1, FC¼3.89,
FDR.BH< 0.5%), have much stronger down-regulations as
compared to the other Cdk and Cyc genes (Table 2). Binding of
CycA with Cdk1 is required for the G2/M transition,
[15] binding
of CycA with Cdk2 plays an important role in S phase
progression and DNA replication,[44] and binding of CycB with
Cdk1 is required for mitosis.[15] The strong down-regulation of
CycA, CycB, and Cdk1 genes in the ActiCHO process agrees with
the observed arrest of the cell cycle in G2/M phase and indicates aAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Table 2. Fold change (FC) cell cycle related genes from culture days 3
to 7 in the culture with cell size increase (ActiCHO) and with no cell
size increase (FortiCHO).
FC. ActiCHO FDR.BH FC. FortiCHO FDR.BH
Cyclin-dependent kinase (Cdk) (promote)
Cdk1 3.89 <0.5% 1.17 9%
Cdk2 2.29 <0.5% 1.76 <0.5%
Cdk4 2.19 <0.5% 1.36 <0.5%
Cdk5 1.47 <0.5% 1.03 81%
Cdk6 1.74 <0.5% 1.02 79%
Cdk15 1.55 1% 2.21 <0.5%
Cyclin (Cyc) (promote)
Ccna2 14.97 <0.5% 1.77 <0.5%
Ccnb2 14.63 <0.5% 1.60 <0.5%
Ccnb1 11.20 <0.5% 1.64 <0.5%
Ccne2 3.09 <0.5% 1.85 <0.5%
Ccnf 2.63 <0.5% 1.68 <0.5%
Ccne1 2.31 <0.5% 2.58 <0.5%
Ccng1 1.41 <0.5% 1.22 3%
Ccng2 2.34 <0.5% 1.70 <0.5%
Cyclin-dependent kinase inhibitor (CDKN) (arrest)
Cdkn2a 1.62 <0.5% 1.11 24%
Cdkn1a 1.73 <0.5% 1.28 <0.5%
Transforming growth factor beta (TGFβ) (arrest)
Tgfb3 2.13 <0.5% 1.02 93%
Tgfbr2 1.61 <0.5% 1.15 1%
Checkpoint kinase (CHEK) (arrest)
Chek1 2.80 <0.5% 1.37 <0.5%
Chek2 2.47 <0.5% 1.23 6%
Tumor protein p53 (P53) (arrest)
Tp53 1.77 <0.5% 1.79 <0.5%
Positivevaluesmeanup-regulationandnegativevaluesmeandown-regulation.Genes
with a FDR.BH< 5% and the absolute FC> 1.4 are considered significant and are
shown here. (Arrest) means the genes promote cell cycle arrest whereas (promote)
means the genes promote cell cycle progression. The results generated are based on
three bioreactor cultures for both the ActiCHO and the FortiCHO process.
www.advancedsciencenews.com www.biotechnology-journal.comdelay in S phase and mitosis. In addition, binding CycE with
Cdk2 is required for progression through the G1/S phase.
[45] The
down-regulation of Cdk2 (FC¼2.29, FDR.BH< 0.5%) may be
related to the cell cycle arrest in the G1 phase.
In order to find the cause of the cell cycle arrest, next,
signaling pathways that coordinate the cell cycle are studied. The
cell cycle activities are regulated by a number of Cdk inhibitors
(Cdkns) such as p16INK4a (Cdkn2a), p21CIP1 (Cdkn1a), and
p27KIP1 (Cdkn1b)[15] (Figure 2A). Binding of these Cdkns to the
Cdks inhibits formation of the active Cdk/Cyc complexes, which
suppresses the cell cycle progression.[43] The high up-regulations
of Cdkns (Cdkn2a, FC¼ 1.62, FDR.BH< 0.5%, and Cdkn1a,
FC¼ 1.73, FDR.BH< 0.5%) in the ActiCHO process indicate a
strong cell cycle inhibition (Table 2). In contrast, the Cdkns in the
FortiCHO process showed much less regulation (Cdkn2a,Biotechnol. J. 2019, 14, 1800156 1800156 (7 of 12) © 2018 TheFC¼ 1.11, FDR.BH¼ 24%, and Cdkn1a, FC¼ 1.28, FDR.
BH< 0.5%).
Cell cycle inhibitors can be activated by intracellular stimuli
(e.g., DNA damage), or extracellular stimuli (e.g., deprivation of
mitogenic factors).[46] The regulation pathways related to
intracellular DNA damage are shown in Figure 2B. Upon
sensing DNA damage, checkpoint kinases (encoded by Chek1
and Chek2), and the p53 tumor suppressor protein (encoded by
Tp53) can be phosphorylated and activated, resulting in the G1
and G2 cell cycle inhibition.
[47] Although these steps are
regulated via post-transcriptional phosphorylation, the signifi-
cant down-regulations of Chek1, Chek2, and Tp53 genes in both
of the two processes (Table 2) imply that DNA damage is less
likely the cause of the cell cycle arrest. With regard to
extracellular stimuli, the p21CIP1 can be induced by transforming
growth factor beta (TGFβ, encoded by Tgfb), which acts as a
negative paracrine/autocrine growth factor in growth regula-
tion,[48–50] as shown in Figure 2A. The TGFβ protein is activated
from its latent complex upon sensing various environmental
stresses such as ROS,[51] hypoxic conditions,[52] pH,[53] and
proteases.[54] As mentioned before, the DO and pH are well
controlled during both the ActiCHO and the FortiCHO
processes. Furthermore, at the point where cell size started to
increase in the ActiCHO process (culture day 4, Figure 1A), the
biomass concentration of both process are comparable,
therefore, ROS and hypoxia are not likely the cause of different
TGFβ activities in both processes and through that play a role in
cell size increase. The TGFβ signaling pathway is initiated by
binding of TGFβ to TGFβ receptors (types I and II encoded by
Tgfbr1 and Tgfbr2) and subsequently, induces p27KIP1 and p21CIP1
leading to the cell cycle inhibition (Figure 2A). The higher up-
regulations of both the Tgfb (Tgfb3, FC¼ 2.13, FDR.BH< 0.5%)
and Tgfbr (Tgfbr2, FC¼ 1.61, FDR.BH< 0.5%) genes in the
ActiCHO process (Table 2) indicate a higher TGFβ signaling
activity. In addition, expression of CycD is strongly dependent on
extracellular mitogens. The CycD/CDK4, 6 complexes, therefore,
function early in G1 and act as mitogen sensors (Figure 2A).
[55]
The CycD genes (ccnd1, ccnd2, and ccnd3) are not regulated in the
ActiCHO process (Supporting Information 1), indicating that
deprivation of extracellular mitogens is not likely the cause of cell
cycle arrest in the G1 phase. However, looking at the expression
of various mitogen-activated protein kinases (Supporting
Information 1), we find both significant up- and down-
regulations in the ActiCHO process. Therefore, it is not certain
whether lacking of mitogen is the cause of the cell cycle arrest in
the phases other than G1. In summary, the result from
transcriptome analysis implies that the cell cycle arrest in the
ActiCHO process was caused by an activation of cell cycle
inhibitors and down-regulation of Cdks and cyclins in reaction
to extracellular environmental stresses and/or depletion of
mitogen(s).3.2.3. Gene Regulation Related to Cell Growth
Besides the cell cycle arrest, a continued biomass production is
the other essential aspect for cell size increase. In this context, we
found that in agreement with literature, the mTOR pathway is
playing a central role in manipulating the cell biomass growth ofAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comthe ActiCHO process. mTOR integrates the extracellular and
intracellular signals through a number of upstream pathways,
and regulates cell growth through its downstream effectors.[56]
The regulation of these pathways in the ActiCHO process are
summarized in Figure 2C–F. In addition, the significantly
regulated genes involved in these pathways are shown in Table 2.
First of all, the downstream effectors of mTOR are studied.
The activity of these effectors are regulated by mTOR in
transcriptional and/or post-transcriptional approaches. Activa-
tion of mTOR results in phosphorylation of the eukaryotic
initiation factor 4E-binding proteins (4EBPs). The phosphory-
lation prevents binding of these proteins to the eukaryotic
initiation factor eIF4E.[10] This results in increased activity of
eIF4E, which promotes protein translation.[57] In the ActiCHO
process, the eukaryotic initiation factor 4E-binding protein
(4EBP) genes are significantly down-regulated (Eif4ebp1, FC¼
2.53, FDR.BH< 0.5% and Eif4ebp2, FC¼1.40, FDR.BH
< 0.5%). The down-regulation of 4EBP genes may have resulted
in less binding to eIF4E and thus, released the activity of protein
synthesis (see Figure 2E). As a result, the protein synthesis rate
in the ActiCHO process remained high during the size increase
phase. In contrast, the 4EBP genes are not regulated (Eif4ebp1,
FC¼1.06, FDR.BH¼ 67% and Eif4ebp2, FC¼1.09 FDR.
BH¼ 40%) in the FortiCHO process, which agrees with the
stopped cell growth in this process.
High mTOR activity also positively regulates the synthesis of
lipids[58] which is a necessary component for cell growth (see
Figure 2F). An increase in mTOR complex 1 (mTORC1) activity
was reported to increase the sterol responsive element binding
protein (SREBP) activity which led to higher lipid synthesis
rate.[59] The higher up-regulation of the SREBP gene (Srebf1,
FC¼ 1.47, FDR.BH¼ 3%) in the ActiCHO process correlates
with the slightly higher fatty acid synthesis rate during the cell
size increase phase compared to the proliferation phase and the
formation of lipid droplets, as shown in our previous study.[18] In
contrast, the SREBP gene is not regulated (FC¼1.02, FDR.
BH¼ 94%) in the FortiCHO process. In addition to by mTOR,
lipid synthesis was also shown to be induced by Akt which is a
positive upstream regulator of mTOR. Akt induces lipid
synthesis by up-regulating the ATP citrate lyase (encoded by
Acly gene) activity. ATP citrate lyase is a key enzyme that
catalyzes the reaction from citrate to cytosolic oxaloacetate and
acetyl-CoA.[60] The latter one is a precursor for lipogenesis. In the
ActiCHO process, the transcriptional activity of the Acly
gene remained unchanged (FC¼1.03, FDR.BH¼ 72%, see
Supporting Information 1) whereas in the FortiCHO process, it
decreased significantly (FC¼1.87, FDR.BH< 0.5%, see
Supporting Information 1). In agreement with the transcrip-
tome data, the fatty acids synthesis rate in the ActiCHO process
was maintained more or less constant during the cell size
increase phase as compared to the exponential growth phase. In
contrast, the pathways related to lipid synthesis experienced
significant down-regulations in the FortiCHO process, which
agrees with the fact that the cells went from the exponential
growth phase on day 3 to the stationary phase on day 7 since the
requirement for lipids went down.
Next, cascade pathways upstream of mTOR that channel
extracellular signals to mTOR were studied (Figure 2C,D,F). The
differentially expressed genes in these pathways are shown inBiotechnol. J. 2019, 14, 1800156 1800156 (8 of 12) © 2018 TheTable 3. The presence of extracellular growth factors and
nutrients are essential to the growth and biomass synthesis of
the cells. A lack of either growth factors or nutrients can lead to
growth attenuation, autophagy, and eventually cell death.[61] The
concentration of extracellular growth factors and nutrients is
sensed by the cells through a number of signaling pathways. The
signal of growth factors, such as insulin-like growth factors
(IGF), is channeled through the PI3K-Akt pathway.[62] The signal
transduction starts with the binding of IGF to the IGF binding
protein (IGFBP, encoded by Igfbps genes).[63] Next, the binding of
IGF with IGFBP phosphorylates phosphatidylinositol (4,5)
biphosphate (PIP2) to produce PIP3 (Figure 2C).[64] The later
one phosphorylates and activates the Akt pathway which
subsequently promotes the mTOR activity, as mentioned
previously. In the ActiCHO process, Igfbps showed stronger
up-regulations (Igfbps7, FC¼ 1.90, FDR.BH< 0.5%, and Igfbps4,
FC¼ 1.51, FDR.BH< 0.5%) compared to in the FortiCHO
process (Igfbps7, FC¼ 1.15, FDR.BH¼ 57%, and Igfbps4, FC¼
1.34, FDR.BH< 0.5%) (Table 3). In agreement with this, it also
can be seen in Table 3 that the PI3K (Pik3ip1 and Pik3c2a) genes
are significantly up-regulated in the ActiCHO process.
Besides the PI3K pathway, increasing evidence suggests that
cytokines, such as tumor necrosis factor-α (TNFα) through the
inhibitor of nuclear factor-κB kinase-β (IKKβ) mediated pathway,
can also induce the Akt activity.[65] It can be seen in Table 3 that
various genes for the TNFα-induced proteins (Tnfaip) are
up-regulated much stronger in the ActiCHO process compared
to in the FortiCHO process. Both the PI3K and the TNFα-IKKβ
pathways have a similar expression pattern in the ActiCHO
process, and both have a positive contribution to the Akt activity.
This together demonstrates that the extracellular growth factors
and cytokines are likely the important factors for the activation of
the Akt and subsequently the mTOR activity, meaning that they
are also likely the cause of the cell size increase after the cell cycle
inhibition.
In addition to the growth factors and cytokines, sufficient
extracellular amino acids concentrations are needed to
maintain the mammalian cell growth. The signaling pathways
related to sensing the amino acid levels are illustrated in
Figure 2D. Sufficient amino acid levels stimulate the vacuolar
Hþ-ATPase (v-ATPase) on the lysosomal membrane,[66] leading
to hydrolysis of ATP by v-ATPase. This signal stimulates the
regulator complex (encoded by the late endosomal/lysosomal
adaptor, Lamtor genes) activity. The regulator complex acts as a
guanine exchange factor converting RagA/B GDP to RagA/
B GTP.[66] The latter one can bind to and activate the mTORC1.
As can be seen in Table 3, several V-ATPase and Lamtor genes
show higher up-regulation in the ActiCHO process compared
to in the FortiCHO process, implying that the signals from the
amino acids sensing pathways also play a role in promoting the
mTOR activity for the continued biomass growth in the
ActiCHO process. As can be seen in Figure S5, Supporting
Information, amino acid concentrations in the FortiCHO
process are substantially different from those in the ActiCHO
process, which may have caused the differences in growth
behavior, although it cannot be excluded that other factors in
the complex media are involved. The higher concentrations of
amino acids in the ActiCHO process does correlate with the
higher activity of the amino acid sensing pathways in thisAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Table 3. Fold change (FC) mTOR upstream and downstream genes
from culture days 3 to 7 in the culture with cell size increase
(ActiCHO) and with no cell size increase (FortiCHO).
FC. ActiCHO FDR.BH FC. FortiCHO FDR.BH
mTOR downstream effectors
Eukaryotic translation initiation factor 4E-binding protein (4EBP) (inhibit)
Eif4ebp1 2.53 <0.5% 1.06 67%
Eif4ebp2 1.40 <0.5% 1.09 40%
Sterol regulatory element-binding protein (SREBP) (promote)
Srebf1 1.47 3% 1.02 94%
mTOR upstream regulators
Insulin-Like Growth Factor-binding protein (IGFBP) (promote)
Igfbp7 1.90 <0.5% 1.15 57%
Igfbp4 1.51 <0.5% 1.34 <0.5%
TNF alpha induced protein (TNFaIP) (promote)
Tnfaip6 4.21 <0.5% 1.55 1%
Tnfaip2 3.32 <0.5% 1.05 84%
Tnfaip8 1.69 <0.5% 1.22 20%
Tnfaip1 1.41 <0.5% 1.06 64%
Tnfaip3 1.43 <0.5% 1.30 2%
Phosphoinositide 3-kinase (PI3K) (promote)
Pik3ip1 2.01 <0.5% 1.47 3%
Pik3c2a 1.76 <0.5% 1.01 94%
Protein kinase B (PKB/AKT) (promote)
Akt2 1.40 <0.5% 1.12 4%
Tuberous sclerosis complex (TSC) (inhibit)
Tsc2 1.45 <0.5% 1.11 18%
Vacuolar-type Hþ-ATPase (V-ATPase) (promote)
Atp6v1f 1.64 <0.5% 1.23 5%
Atp6v1a 1.62 <0.5% 1.26 <0.5%
Atp6v1b2 1.54 <0.5% 1.45 <0.5%
Atp6v1e1 1.43 <0.5% 1.16 3%
Late endosomal/lysosomal adaptor, MAPK and MTOR activator (Lamtor)
(promote)
Lamtor2 1.51 <0.5% 1.08 58%
Lamtor4 1.22 4% 1.23 7%
Lamtor5 1.2 3% 1.01 93%
AMP-activated protein kinase (AMPK) (inhibit)
Prkaa1 1.42 <0.5% 1.08 32%
Growth arrest specific (GAS) (inhibit)
Gas2 5.77 <0.5% 1.95 <0.5%
Gas2l3 5.66 <0.5% 1.18 11%
Gas7 1.78 <0.5% 1.30 13%
Positive values mean up-regulation and negative values mean down-regulation.
Genes with a FDR.BH< 5% and the absolute FC> 1.4 are considered significant
and shown here. (Promote) means the genes promote biomass synthesis whereas
(inhibit) means the genes hamper biomass synthesis. The results generated are
based on three bioreactor cultures for both the ActiCHO and the FortiCHO
process.
www.advancedsciencenews.com www.biotechnology-journal.com
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of the V-ATPase and Lamtor genes.
Glucose is a major nutrient for CHO cell lines. The
characteristic consumption rate of glucose and the concomitant
production rate of lactate are typically high in CHO cell lines. In
addition, as shown in our previous study,[24] the specific glucose
consumption rate during the size increase phase of the ActiCHO
process is significantly higher than it is during the stationary
phase of the FortiCHO process, which can also be seen in
Figure S4, Supporting Information. The high glucose consump-
tion is likely the result of a high glycolysis activity and will
correspondingly result in a high intracellular ATP/AMP ratio.
The high ATP/AMP ratio can suppress the AMP-activated
protein kinase (AMPK) activity[67] and lead to an increased
mTOR activity through phosphorylation (Figure 2F). In this
study, we are unable to confirm the state of the ATP/AMP ratio.
However, one AMPK transcript (Prkaa1) showed an up-
regulation in the ActiCHO process (Table 3). Assuming the
AMPK pathway is also regulated transcriptionally, this implies a
decrease in the ATP/AMP ratio. In this regard, the high specific
glucose consumption rate (Figure S4, Supporting Information)
seems to play no role in activating mTOR during the cell size
increase of the ActiCHO process.
Furthermore, several growth arrest specific (Gas) genes showed
high (>5 FC) down-regulations in the ActiCHO process (Table 3).
Expressionof theGasprotein family is strictly related to thegrowth
arrest state of mammalian cells[68,69] (see Figure 2E) and may be
involved in various cellular activities including microfilaments
reorganization, cell cycle, DNA synthesis, and apoptosis.[68,70,71]
Smith and Steitz[72] showed that upon reduction of the mTOR
activity, Gas5 transcript levels increased. Recently, the Gas5
transcript was shown to be an important tumor suppressor
involved in various cancers.[73] In addition, the expression ofGas2
transcript has been shown to play a critical role in preventing
cancer transformation by leading the cells to a premature
senescence.[74] In the present work, greater down-regulations of
the Gas genes in the ActiCHO process correlates with the
continued cell growth in the ActiCHO process. It is, however, not
fully clearhowtheseGasgenes interactwith intra-andextracellular
signals to participate in growth control.
Summarizing this section, it was shown that the mTOR
upstream and downstream pathways were regulated in a
strongly synchronized pattern in the ActiCHO process, leading
to a higher mTOR activity in this process. In the FortiCHO
process, this was not observed. These results demonstrate that
the activation of mTOR plays an essential role in the continued
biomass growth after the stop of cell cycle progression.
Furthermore, the activation of mTOR is closely related to the
extracellular growth factors, cytokines, and amino acids levels,
indicating that the cell size increase is related to these
extracellular conditions.3.3. Extracellular Stimuli for the Cell Size Increase
The cell size increase in this study is associated with the cell cycle
arrest and the continued biomass formation. Two genes involved
in osmotic regulation (Slc6a12 and Scn7a) showed up in the top
10 up-regulated fold changes (Table 1). However, in a perfusionAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comprocess using the same cell line and the ActiCHO-P medium as
perfusion medium, a comparable change in cell size was
observed (data not shown). In that experiment, the ActiCHO
feed A/B was not used and the culture osmolality was constant. It
can therefore be concluded that the cell cycle arrest and the
concomitant cell size increase are not related to the osmolality
nor to a unique feature of the ActiCHO feed A/B.
A significant cell cycle arrest was observed in the ActiCHO
process. Cell cycle arrest could be caused by secretion of toxic
metabolites (e.g., ammonium and lactate) or paracrine/auto-
crine proteins (e.g., TGFβ). Cell division stopped and cell size
started to increase on day 4. At this time the lactate and
ammonium concentrations were about 25 and 3mM, respec-
tively. Based on a survey on all our experiments done in
controlled bioreactors with the same cell line in different media
systems (unpublished), the cells can still divide rapidly at lactate
and ammonium concentrations of 40 and 5mM, respectively.
Thus, ammonium and lactate are not likely the cause of the cell
cycle arrest. The TGFβ pathway is significantly up-regulated in
the ActiCHO process, which may have caused cell cycle arrest.
Another cause of the cell cycle arrest could be depletion of certain
nutrients or mitogenic factors. If this was the case, these
nutrients or mitogenic factors should not be present in the feeds
or that the depletion causes irreversible cell cycle arrest which
cannot be released by addition of the depleted nutrients
anymore. This means that these factors are absent or not
present in sufficient amounts in the feed. It could also be that
depletion of a nutrient in the batch period causes the cells to
enter a non-proliferative state from which it cannot recover by
later addition of that nutrient. For example, in Figure S5,
Supporting Information, it can be seen that in the ActiCHO
process some non-essential amino acids including asparagine,
glutamine, and cystine were depleted around the point where
cells stopped dividing and started increasing size (day 5).
Fomina-Yadlin et al.[75] reported that depletion of individual
amino acid can activate the amino acid response pathway (AAR),
resulting in an overexpression of activating transcription factor 4
(ATF4). Consequently, cells experience down-regulation of cell
cycle progression, DNA replication, nucleotide biosynthesis, and
lipid metabolism. However, in the present study, the ATF4 gene
(ATF4) was significantly down-regulated from days 3 to 7
(FC¼4.2, FDR.BH< 0.5%, Supporting Information 1), indi-
cating that the AAR pathway was not triggered on day 7. Since
depletion occurred at day 3 and was resolved by feed addition at
day 7, it could still be that a temporary overexpression between
days 3 and 7 of ATF4 triggered the AAR pathway at the moment
of depletion of certain amino acid(s) and caused an irreversible
cell cycle arrest. In the meantime, the high concentration of the
other amino acids (see Figure S5, Supporting Information)
keeps the mTOR activity high resulting in continued biomass
production and cell size increase. Note that in the FortiCHO
process, the same non-essential amino acids asparagine,
glutamine, and cystine were also depleted around day 5.
However, the other amino acids levels are significantly lower
compared to in the ActiCHO process, which may be related to
the lower mTOR activity in the FortiCHO process. This
hypothesis, however, needs to be further confirmed by a higher
time resolution for the transcriptome data and by tuning the
amino acids ratio in the ActiCHO process.Biotechnol. J. 2019, 14, 1800156 1800156 (10 of 12) © 2018 TheSince cell size increase is positively correlated to the increase
in cell specific recombinant protein productivity, it would be
beneficial to design the medium and feed system in a way to
trigger the cell size increase in a fed-batch culture process
through, for example, inducing the mTOR activity. On the other
hand, since biomass continues to grow after the stop of cell
division in such a process, the nutrients provided to the culture
should contain not only nutrients assigned for maintenance and
mAb production reactions, but also all the precursors and
building blocks for biomass growth.[18]4. Conclusion
We performed a transcriptome analysis to identify the molecular
mechanism associated with cell size increase for a CHO fed-
batch process. Looking at the top 10-fold changes of up- and
down-regulated genes in the ActiCHO process, genes related to
redox regulation, protein transport, and osmotic regulations
were highly up-regulated. This result indicates that cells adapted
transcriptionally to cope with redox and osmotic changes during
the culture process. In addition, the top 10 down-regulated genes
were related to cell cycle regulation andmitosis. This agrees with
the observed cell size increase and cell cycle arrest in the
ActiCHO process. In the next step, genes involved in cell cycle
progression and biomass growth as well as in the signaling
pathways of these processes were selected for further analysis. It
was found that various cyclin (cyc) and cdk genes were
significantly down-regulated in the ActiCHO process, and a
number of Cdk inhibitors (Cdkns) were significantly up-
regulated, which agrees with the cell cycle arrest in both the
G0/G1 and the G2/M phase. The gene expression results also
indicate that the cell cycle arrest is not caused by DNA damage.
Looking at the genes involved in regulation of biomass growth,
the mTOR upstream and downstream pathways are regulated in
a strongly synchronized pattern to stimulate the mTOR activity
in the ActiCHO process. This agrees with a continued cell
growth after cell cycle arrest. It is possible that the production of
TGFβ as a negative paracrine/autocrine factor, or the depletion
of certain nutrients and/or mitogenic factors in the basal
medium resulted in the cell cycle arrest. Meanwhile, extracellu-
lar growth factors and high nutrients levels keep channeling the
mTOR activity to maintain biomass production. This study
showed that the continued biomass growth after the cell cycle
arrest is related to the extracellular nutrient levels. Hence, by
rational design of media and feeds, it may be possible to
manipulate CHO cell size during industrial culture processes,
which will further improve cell growth and specific productivity.Supporting Information
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